Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies

Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced today a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials. Science 37 is licensing access to its proprietary software platform, NORA^® (Network Oriented Research Assistant), which leverages mobile technology and telemedicine capabilities, enabling patients to participate in clinical research studies regardless of their geographical location. The new collaboration brings together Science 37’s technology for running remote clinical trials and Boehringer Ingelheim’s extensive capabilities in drug discovery and clinical development of novel treatments.

“Patient Centricity is a key driver for our pipeline and portfolio. Our mission is to bring novel value added therapies to patients. By leveraging a platform such as NORA^®, we will be able to allow patients to participate in clinical trials on their schedule and timetable. This is pivotal in ensuring patients feel they are invaluable partners in helping us to develop and deliver novel therapies worldwide” said Thor Voigt MD/PhD, Chief Medical Officer of Boehringer Ingelheim.

The NORA^® platform enables end-to-end virtual or remote clinical trials and adheres to the highest industry quality and regulatory standards. Unlike other mobile health technology companies, Science 37’s remote clinical trial model – called the Metasite™ – helps researchers engage directly with trial participants through every stage of the trial, from screening and recruitment to telemedicine-based patient care to data lock. This direct connection online allows for greater retention of patients, increased diversity across trials, and significantly faster recruitment. The patient’s data are sent securely via NORA^® to researchers who can immediately access information that would otherwise have to be collected by medical personnel through face-to-face interactions at study centers. The platform can also be used to remind patients to take their study medications at the proper time and let researchers know if participants are adhering to the study requirements.

“We’ve designed NORA^® as a platform that provides researchers flexible options for how and where to collect evidence,” says Chris Ceppi, Science 37’s Chief Product Officer. “Our collaboration with Boehringer Ingelheim allows us to do even more virtual trials on a larger scale - which is great news for both patients and scientists.”

This technology enterprise collaboration agreement between Boehringer Ingelheim and Science 37 positions both companies in the forefront of the global digital health transformation. Science 37’s NORA^® technology will allow Boehringer Ingelheim to accelerate enrollment and improve the participant experience with decreased patient burden, better patient retention and reduced total trial time. In addition to providing access to NORA^®, Science 37 will advise on study design, protocol development, and regulatory strategy based on its unique experience in running remote clinical trials. Additionally, Boehringer Ingelheim will have the option to enlist Science 37’s teams to provide a variety of Metasite™ trial services, including principal investigators, clinical research coordinators, and patient recruitment strategies.

“When an industry leader in innovation such as Boehringer Ingelheim makes a commitment of this magnitude it signals a bright future for the patient-centered Metasite approach to clinical trials, and we’re glad we can help support it,” says Noah Craft, MD, PhD and Co-Founder and CEO of Science 37. “We appreciate the confidence Boehringer Ingelheim has shown in Science 37 and our position as the leading technology provider for remote clinical trials.”

Boehringer Ingelheim’s technology enterprise collaboration agreement with Science 37 covers use of its NORA^® technology across the U.S. with plans to expand internationally in the future.

“While the U.S. is the starting point for exploration of this technological collaborative partnership we are committed to our patients globally. We aim to expand this new approach and democratize the concept of clinical research and drug development worldwide.” said Lilija Kircheis,MD,PhD, Head Global Clinical Operations, Boehringer Ingelheim.

Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/virtual-clinical-trial-collaboration-science-37

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190103005363/en/

Contact information

Media Contact
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications, Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

Science 37
Aryana Hosseinkhani
Corporate Marketing and Communications
P : +1 310-507-9531
pr@science37.com